Latest from University of Chicago Medicine Comprehensive Cancer Center

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.
Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.
Michael J. Thirman, MD, further discusses the novel compound, SNDX-5613, and sheds light on the next steps for this research.
Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.
Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.
Michael J. Thirman, MD, discusses the clinical rationale for using the investigational agent SNDX-5613 to treat a subtype of acute myeloid leukemia and acute lymphoblastic leukemia.
Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.
This week we have collaborated with The University of Chicago Medicine to highlight important topics facing oncologists today. Join us Saturday, May 16, 2020 at 11 AM EST.
Publication Bottom Border
Border Publication
x